Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
University of California, San Francisco
Wake Forest University Health Sciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Context Therapeutics Inc.
OncoC4, Inc.
Parabilis Medicines, Inc.
Jazz Pharmaceuticals
Compass Therapeutics
Bayer
Centre hospitalier de l'Université de Montréal (CHUM)
Agenus Inc.
858 Therapeutics, Inc.
GlaxoSmithKline
SystImmune Inc.
Rutgers, The State University of New Jersey
Eli Lilly and Company
Xencor, Inc.
Atavistik Bio, Inc
PMV Pharmaceuticals, Inc
Mayo Clinic
University of Michigan Rogel Cancer Center
Alterome Therapeutics, Inc.
Rutgers, The State University of New Jersey
BeOne Medicines
Psyence Australia Pty Ltd
Genmab
Kaiser Permanente
Children's Oncology Group
Duke University
AstraZeneca
Myeloid Therapeutics
Tizona Therapeutics, Inc
Daiichi Sankyo
BioNTech SE
IDEAYA Biosciences
MacroGenics
Daiichi Sankyo
Doma Biopharmaceutical(Suzhou)Co., Ltd.
Second Life Therapeutics
M.D. Anderson Cancer Center
Medical College of Wisconsin
Dren Bio
Mayo Clinic
Sairopa B.V.
Tanabe Pharma America, Inc.
RenJi Hospital
NeoTX Therapeutics Ltd.
West China Hospital
Tempus AI